New Therapeutic Options for Stroke Prevention in Atrial Fibrillation

Authors

Joseph Jackson, PhD, Program Director for Applied Economics and Outcomes Research, Jefferson School of Population HealthFollow

Document Type

Podcast

Presentation Date

2-13-2013

Abstract

This Forum presentation focuses on the clinical needs for the population at risk of strokes in atrial fibrillation (afib). For more than 50 years warfarin has stood alone as the gold standard therapy for the prevention of strokes in afib. Recently the FDA has approved three new Novel Oral AntiCoagulants (NOACs) to compete with warfarin. This session explores how these new therapies measure up: clinically, in the real world, and economically.
PowerPoint slides attached below. 45 slides. Presentation: 50 minutes

Recommended Citation